AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02790099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
Study NCT01400490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation
Study NCT01400490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation
Study NCT01554670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF micro-tenotomy
Description: an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
Study NCT02522884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 to 80 mg of atorvastatin each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 to 80 mg of atorvastatin each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 2000 mg of niacin each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: 3.8 g of colesevelam each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Niacin
Description: Placebo niacin each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Colesevelam
Description: Placebo colesevelam each day
Study NCT00715273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Colesevelam
Description: Placebo colesevelam each day
Study NCT02509507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
Study NCT02509507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
Study NCT00806403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reteplase 10+10 U
Description: comparison to primary PCI
Study NCT00806403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary PCI
Description: comparison to thrombolysis
Study NCT04689191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group A and C meningococcal polysaccharide vaccine
Description: One dose of Experimental Group A and C meningococcal polysaccharide vaccine
Study NCT02320604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of study drug
Description: i.v. administration of Ambisome in two different dossages
Study NCT05487508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of intraoperative 1 mg/kg body weight dexamethasone
Study NCT05487508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo (NaCl 0.9%)
Study NCT01360151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
Study NCT01360151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
Study NCT01360151 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ranibizumab(Lucentis), verteporfin(Visudyne)
Description: ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
Study NCT04325659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Device
Description: An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
Study NCT04325659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT01690520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT01690520 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo high dose or middle intensity TBI
Study NCT01690520 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high dose or middle intensity TBI
Study NCT01690520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
Study NCT01690520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
Study NCT01802840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: biscuits supplemented with soy fiber
Description: Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
Study NCT01802840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: biscuits supplemented with soy fiber
Description: Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
Study NCT03101579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study NCT03101579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study NCT03101579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Study NCT03101579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
Study NCT04667273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation.
Study NCT04667273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Description: Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband.
Study NCT04667273 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise Training (ET)
Description: Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband.
Study NCT03639961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated leading, managing and governing for results model
Description: Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
Study NCT03639961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model
Description: Traditional model is a health service delivery model already in place in the government health system.
Study NCT01165242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: One intramuscular injection
Study NCT01165242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: One intramuscular injection
Study NCT02360397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranolazine
Description: Ranolazine 1000 mg tablet twice daily for 30 days
Study NCT02751060 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04311138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community-based reablement service
Description: Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
Study NCT04311138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multicomponent training
Description: control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
Study NCT01204060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal allergen challenge
Description: Subjects will receive a nasal spray containing an allergen to which they are allergic
Study NCT01204060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal placebo challenge
Description: Subjects will receive a nasal spray with allergen diluent
Study NCT01894113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transbronchial lung biopsy
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU)
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01653470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study NCT03580759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB
Description: After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
Study NCT01361906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensomotoric training
Description: The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today.
Study NCT02431481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg
Study NCT02885935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended protein intake
Description: Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
Study NCT02885935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated protein intake
Description: Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
Study NCT01456702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: risk stratification group
Description: goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
Study NCT02104128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
Study NCT02082912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
Study NCT02082912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
Study NCT02082912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandMentor Pro
Description: The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
Study NCT02082912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HandMentor Pro
Description: The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
Study NCT04365283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New Bioactive Restorative Material (ACTIVA Presto)
Description: New Bioactive Restorative Material
Study NCT04365283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)
Description: High Viscosity Glass Hybrid Reinforced Glass Ionomer
Study NCT02177747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy conducted using a smartphone equipped with a compact addon
Study NCT02177747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study NCT00833547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg of eszopiclone at bedtime on two consecutive nights
Study NCT00833547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Study NCT04719247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
Study NCT04719247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
Study NCT04325659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
Study NCT04325659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
Study NCT04689191 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group A and C meningococcal polysaccharide vaccine
Description: One dose of Control Group A and C meningococcal polysaccharide vaccine
Study NCT01017874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.